EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSTNIG00000014701
Gene Symbol: CACNA2D2
2 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSTNIG00000015012
Gene Symbol: CACNA2D3
3 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSTNIG00000004494
Gene Symbol: CACNA2D4
2 Cross references
228 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSTNIG00000007578
Gene Symbol: CACNA2D4
2 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSTNIG00000015098
Gene Symbol: CACNB3
2 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSTNIG00000015695
Gene Symbol: CACNB4
2 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1

Ensembl ID : ENSTNIG00000011943
Gene Symbol: CACNG1
2 Cross references
194 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSTNIG00000011265
Gene Symbol: CACNG2
2 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSTNIG00000000834
Gene Symbol: CACNG2
2 Cross references
204 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSTNIG00000018825
Gene Symbol: CACNG2
2 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSTNIG00000008105
Gene Symbol: CACNG6
2 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSTNIG00000008103
Gene Symbol: CACNG7
2 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).